A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Pyrotinib (Primary) ; Anastrozole; Aromatase inhibitors; Exemestane; Letrozole; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
Most Recent Events
- 13 Jul 2020 Trial design published in the BMC Cancer
- 12 Apr 2019 New trial record